Phase II Trial of Opaganib Addition in Metastatic Castration‐Resistant Prostate Cancer After Disease Progression on Abiraterone or Enzalutamide

ABSTRACT Introduction Opaganib is a first‐in‐class oral sphingolipid metabolism inhibitor that inhibits sphingosinekinase 2 (SphK2) and dihydroceramide desaturase (DES) and that has a demonstrated safety and preliminary anti‐cancer activity signal in a Phase I study. Methods In this phase II trial,...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Jacqueline T. Brown, Bassel Nazha, Anna C. Ferreira, Kent Armeson, Elizabeth G. Hill, Besim Ogretmen, Shikhar Mehrotra, Alan Brisendine, George Magrath, Terry F. Plasse, Theodore Stewart Gourdin, Omer Kucuk, Michael Lilly
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Wiley 2026-04-01
Edice:	Cancer Medicine
Témata:	abiraterone enzalutamide opaganib prostate cancer sphingolipid
On-line přístup:	https://doi.org/10.1002/cam4.71633
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!